Skip to main content
Clinical Trials/IRCT20181130041802N1
IRCT20181130041802N1RecruitingPhase 3

Effect of 12 point inferior extremity ghams on knee pain relief

Tehran University of Medical Sciences0 sites80 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Phase 3
Status
Recruiting
Enrollment
80

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
35 years to no limit (—)
Sex
All

Inclusion Criteria

  • Complete vigilance and satisfaction.
  • Age over 35 years old.
  • Diagnosis of osteoarthritis according to the American Society of Rheumatology: Having knee pain and having at least 5 of the 8 cases
  • Not using a variety of complementary therapies during the previous three months
  • Lack of personalized sedative medications and drug by the patient
  • The absence of severe neuropathy in the patient.
  • Healthy areas under massage
  • Lack of mental retardation, blindness and deafness. The absence of rheumatoid arthritis, fibromyalgia, acute or recurrent pseudoravirus, malignancy, internal disease, Such as kidney or liver disorder, gastrointestinal bleeding, asthma requiring corticosteroid administration
  • Non-use of corticosteroid in less than 5 weeks, injection of knee depoocorticosteroid in less than 3 months old or intra-articular hyaluronate in less than 6 months
  • A lack of arthroscopy over the past year
  • No significant damage to the knee in less than 6 months
  • Insensitivity and ulcer in the knee.
  • Ability to learn 12 ghams points

Exclusion Criteria

  • Using a variety of complementary therapies during the previous three months
  • Personalized sedative medications and drug by the patient
  • Severe neuropathy in the patient
  • Having mental retardation, blindness and deafness. having the rheumatoid arthritis, fibromyalgia, acute or recurrent pseudoravirus, malignancy, internal disease, Such as kidney or liver disorder, gastrointestinal bleeding, asthma requiring corticosteroid administration
  • Use of corticosteroid in less than 5 weeks, injection of knee depoocorticosteroid in less than 3 months old or intra-articular hyaluronate in less than 6 months
  • Arthroscopy over the past year
  • Significant damage to the knee in less than 6 months
  • Sensitivity and ulcer in the knee

Investigators

Similar Trials